About / News

Total Net Revenues $121.1 Million Net Product Revenues $114.6 Million CUBICIN's 2009 Net U.S. Revenue Guidance Reconfirmed at $520-540 Million

GAAP Basic and Diluted Net Income of $0.14 and $0.13 Per Share, Respectively
NON-GAAP Basic and Diluted Net Income of $0.47 and $0.42 Per Share, Respectively

more

March 27, 2009

Cubist Pharmaceuticals Initiates Phase 2 Trial for Therapy to Reduce Blood Loss During Surgery

more

March 23, 2009

Cubist Pharmaceuticals Files Patent Infringement Lawsuit Against Teva Parenteral Medicines, Inc.

more

February 17, 2009

Phase 1 Trial Begins for Investigational New Drug for MDR Gram-negative Infections -- Second Phase 1 trial to emerge from Cubist's Labs in a week

more

February 13, 2009

Cubist Pharmaceuticals Announces Start of First-in-Human Clinical Trial for Investigational New Drug for Clostridium difficile infections

more

February 10, 2009

Cubist Plans to Commence Patent Infringement Litigation against Teva Parenteral Medicines, Inc. In Response To ANDA filing

Teva Parenteral Medicines, Inc. has submitted an Abbreviated New Drug Application (ANDA) to the FDA for approval to market a generic version of CUBICIN(R) (daptomycin for injection). Cubist plans to file a patent infringement lawsuit against TPM in response to the ANDA filing. more

January 23, 2009

Cubist Pharmaceuticals Reports GAAP Diluted Net Income of $1.82 Per Share in Fourth Quarter 2008 and GAAP Diluted Net Income of $2.56 Per Share for Full Year 2008

Reversal of Cubist's Valuation Allowance for Deferred Tax Assets Benefits Tax Expense by Approximately $127.8 Million 2008 Non-GAAP Diluted Net Income of $1.86 Per Share Earnings Conference Call & Webcast Today (With Slides) at 5:00 p.m. ET more